Variables | OS | DFS | Pelvic control | Distant control | ||||
---|---|---|---|---|---|---|---|---|
HR | p | HR | P | HR | P | HR | P | |
Age (< 65 vs ≥65) | 2.07 (1.27–3.36) | 0.004 | ||||||
Histology (SCC vs AC) | 2.21 (1.31–3.74) | 0.003 | 2.37 (1.57–3.56) | < 0.001 | 2.40 (1.36–4.22) | 0.002 | 2.27 (1.31–3.92) | 0.003 |
FIGO stage (I, II and III-IVA) | 1.84 (1.33–2.56) | < 0.001 | 1.56 (1.20–2.04) | 0.001 | 1.41 (0.96–2.06) | 0.079 | 1.46 (1.03–2.07) | 0.036 |
Tumour size (< 4 cm vs ≥4 cm) | 2.00 (1.28–3.14) | 0.002 | 1.80 (1.27–2.54) | 0.001 | 1.81 (1.08–3.03) | 0.024 | 1.70 (1.10–2.65) | 0.018 |
Para-aortic MLNs (No vs Yes) | 1.28 (0.69–2.40) | 0.434 | 1.40 (0.85–2.33) | 0.188 | 2.42 (1.25–4.68) | 0.008 | 0.73 (0.35–1.56) | 0.420 |
Pelvic MLNs (No vs Yes) | 1.43 (0.91–2.24) | 0.125 | 1.54 (1.08–2.22) | 0.018 | 1.62 (0.97–2.71) | 0.065 | 1.49 (0.93–2.38) | 0.097 |
Common iliac MLNs (No vs Yes) | 1.30 (0.72–2.35) | 0.392 | 1.08 (0.65–1.78) | 0.773 | 0.69 (0.34–1.40) | 0.304 | 1.67 (0.88–3.17) | 0.119 |
Number of pelvic MLNs (continuous) | 1.16 (1.07–1.26) | 0.001 | 1.14 (1.06–1.23) | 0.001 | 1.13 (1.03–1.25) | 0.009 | 1.13 (1.02–1.25) | 0.018 |
Concurrent chemotherapy (No vs Yes) | 0.85 (0.55–1.29) | 0.440 | 0.72 (0.51–1.01) | 0.059 |